Zimlab
Live Price
Recent news and updates for ZIMLAB will appear here soon.
"Robust technical setup for ZIMLAB with strong AI conviction. The bullish trend in the healthcare space is accelerating while RSI at 69 suggests there is still significant room for upside before reaching overbought territory."
Verified by Stockmo Intelligence Grid
Citing cross-referenced internal documents and market technicals
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India.
As of the latest market session, Zimlab (ZIMLAB) is trading at ₹112.99, representing a move of -1.22% from the previous close.
Zimlab is listed and traded under the ticker symbol ZIMLAB on the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE).
Today, Zimlab's stock price moved by -1.22%. Long-term growth trends depend on company financials, technical moving averages, and sector momentum in the Healthcare industry.
Our proprietary AI Momentum engine calculates a 75% bullish probability for ZIMLAB stock over the next 3-5 days. View the live interactive chart on Stockmo to see dynamic technical forecasting.
Over the past 52 weeks, Zimlab shares reached a high of ₹127 and hit a low of ₹59.31.
ZIMLAB exhibits standard volatility for a Healthcare stock, with an average daily trading volume of 43,978 shares. Detailed technical beta indicators are available on the Stockmo charting engine.
Zimlab has a market capitalization of ₹605.05 Cr, designating its size class inside the Healthcare sector.
Zimlab has a current dividend yield of N/A. Companies may adjust payout ratios depending on quarterly earnings growth and reinvestment opportunities.
Zimlab's trailing Price-to-Earnings (P/E) ratio is 94.95. This indicates how much investors are willing to pay for every rupee of the company's annual net earnings.
You can purchase Zimlab (ZIMLAB) shares through any SEBI-registered stockbroker (such as Kite/Zerodha, Groww, or Angel One) by funding your trading account and executing a buy order on the NSE or BSE.
Zimlab's financial health, solvency, growth, and quality metrics are tracked using our proprietary Multibagger V2 score. You can explore ZIMLAB's detailed 5-tier financial scorecard and compare it with market competitors on the Stockmo Multibagger Screener page.
Institutional order blocks and pristine support/resistance triggers for ZIMLAB are monitored in real-time. View live technical entry levels, stop loss bounds, and target prices on our interactive Supply & Demand Trading Engine or scan entire market segments using the Basket Scanner.
Zimlab operates inside the Healthcare sector. You can analyze sector-wide trends, relative strengths, and locate top emerging leaders in this space using our Sector Analysis Hub.